-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – JAB-3068 in Esophageal Squamous Cell Carcinoma (ESCC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.JAB-3068 in Esophageal Squamous Cell Carcinoma (ESCC) Drug Details:JAB-3068 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Paclitaxel in Metastatic Breast Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Paclitaxel in Metastatic Breast Cancer Drug Details: Paclitaxel (DHP-107, Liporaxel) is a taxane derivative,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – 212Pb-DOTAM-GRPR1 in Metastatic Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. 212Pb-DOTAM-GRPR1 in Metastatic Colorectal Cancer Drug Details: 212Pb-DOTAM-GRPR1 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Stenoparib in Follicular Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Stenoparib in Follicular Lymphoma Drug Details:Stenoparib (E-7449) is under development for the treatment of solid tumors,...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BUP-1501 in Cancer Pain
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.BUP-1501 in Cancer PainDrug Details:BUP-1501(buprenorphine) is under development for pain and cancer pain. The drug candidate...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tinostamustine in T-Cell Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tinostamustine in T-Cell Leukemia Drug Details: Tinostamustine (NL-101) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tinostamustine in Epithelial Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tinostamustine in Epithelial Ovarian Cancer Drug Details: Tinostamustine (NL-101) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tinostamustine in Diffuse Large B-Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tinostamustine in Diffuse Large B-Cell Lymphoma Drug Details: Tinostamustine (NL-101) is under development for the...
-
Company Profile
![]()
Norgine BV – Company Profile
Norgine BV (Norgine) develops, manufactures, and commercializes specialty pharmaceuticals and medical devices. The company's product portfolio spans branded drugs and devices in the areas of gastroenterology, hepatology, and cancer and supportive care. It also advances pipeline candidates for the treatment of various gastroenterological and hepatological diseases and disorders. Norgine serves healthcare systems and patients in Europe, New Zealand, and Australia. Its prominent partners include Takeda, Bausch Health, Abeona Therapeutics, Alfasigma, Amicus, China Medical System Holdings, Modi-Mundipharma, Navidea, Noventure, and Olympus...
Add to Basket -
Sector Analysis
Diabetic Neuropathic Pain Market Size, Drug Analysis, Epidemiology, Disease Management, Pipeline Assessment, Unmet Needs and Forecast 2031
Diabetic Neuropathic Pain Market Overview The drug sales across the 7 major markets (7MM) in the Diabetic Neuropathic Pain (DNP) market were estimated at $1.7 billion in 2021. The DNP market is expected to grow at a CAGR of over 5% during 2021-2031. The US market makes up the majority of total global sales, due to the large DNP prevalent population and the high price of medication in the country. Diabetic Neuropathic Pain Market Outlook, 2021-2031 ($ billion) To get...
-
Product Insights
Ovarian Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Ovarian Cancer Pipeline Products Market Report Overview Ovarian cancer is any cancerous growth that may occur in different parts of the ovary. The majority of ovarian cancers arise from the epithelium (outer lining) of the ovary. Signs and symptoms of ovarian cancer include pelvic discomfort or pain, indigestion, gas or nausea, and changes in bowel habits, such as constipation, loss of appetite, and low back pain. The predisposing factors include age and family history. Treatment includes surgery, chemotherapy, and radiation...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – MR-309
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry MR-309 Drug Details MR-309 (E-52862) is under development for the treatment of neuropathic pain...
-
Product Insights
Restless Legs Syndrome Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update
The restless legs syndrome clinical trial market research report provides an overview of the restless legs syndrome clinical trials scenario. The report provides top-line data relating to the clinical trials on restless legs syndrome. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – BUP-1501
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry BUP-1501 Drug Details BUP-1501(buprenorphine) is under development for pain and cancer pain. The drug...
-
Product Insights
Cervical Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Cervical Cancer Drugs Market Report Overview Most cervical cancer is caused by a virus called human papillomavirus, or HPV. Its symptoms of cervical cancer may include abnormal vaginal bleeding, such as bleeding after sex (vaginal intercourse), bleeding after menopause, bleeding, spotting between periods, and having longer or heavier (menstrual) periods than usual. Key Targets Programmed Cell Death Protein 1, Human Papillomavirus Protein E7, Programmed Cell Death 1 Ligand 1, Human Papillomavirus Protein E6, Cytotoxic T Lymphocyte Protein 4, Vascular Endothelial...
-
Product Insights
Cancer Pain Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Cancer pain can be defined as a complex sensation that reflects both damages to the body and the body's response to the damage. Pain may arise due to tumor compressing or infiltrating tissue, from treatments and diagnostic procedures, or skin, nerve, and other changes caused by either the body's immune response or hormones released by the tumor. Cancer pain can be treated by analgesic drug therapy, non-opioid analgesics, opioid analgesics, adjuvant drugs, psychotherapy, anesthetic, and neurosurgical pain management. The Cancer...
-
Product Insights
Peripheral T-Cell Lymphomas (PTCL) Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update
The Peripheral T-Cell Lymphomas (PTCL) clinical trial market research report provides an overview and top-line data relating to the clinical trials on PTCL. The report includes an overview of trials count and their average enrollment in top countries conducted globally. It also includes coverage of disease clinical trials by region and top countries, trial phase, trial status, end points status, and sponsor type. The report also provides prominent drug names and trial counts for in-progress trials (based on the number...
-
Product Insights
Pancreatic Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer – Drugs In Development, 2022, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape. Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may radiate to back, yellowing of skin and the whites of eyes (jaundice), loss of appetite, weight loss, depression and blood...
-
Product Insights
Chemotherapy Induced Peripheral Neuropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Chemotherapy-induced Peripheral Neuropathy - Drugs in Development research report provides a comprehensive overview on the therapeutics under development for Chemotherapy-induced Peripheral Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for...
-
Product Insights
Opium (Opioid) Addiction Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update
The Opium (Opioid) Addiction clinical trial market research report provides an overview of the Opium (Opioid) Addiction clinical trials scenario. The report provides top-line data relating to the clinical trials on Opium (Opioid) Addiction. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.